查詢結果分析
相關文獻
- Intravitreal Triamcinolone Acetonide for Patients with Macular Edema due to Branch Retinal Vein Occlusion
- 以focal ERG評估非增殖性糖尿病視網膜病變的中心凹變化
- The Relation between Branch Retinal Vein Obstruction and Axial Length
- Intravitreal Triamcinolone Injection for Macular Edema Secondary to Increased Retinal Vascular Permeability
- 眼前段受傷行玻璃體切除術後發生於兒童的無晶體性囊狀黃斑部水腫
- 糖尿病網膜病變
- 糖尿病視網膜病變:綜論及治療新趨勢
- Refractory Macular Edema Treated by Intravitreal Adalimumab in a Patient with Central Retinal Vein Occlusion
- Intravitreal Aflibercept Effectively Treating Two Patients with Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab
- Intravitreal Bevacizumab Injections in Cases of Central Retinal Vein Occlusion with Macular Edema--Case Series
頁籤選單縮合
題名 | Intravitreal Triamcinolone Acetonide for Patients with Macular Edema due to Branch Retinal Vein Occlusion=利用玻璃體內注射Triamcinolone Acetonide治療因視網膜分枝靜脈阻塞而導致的黃斑部水腫 |
---|---|
作者 | 鄭凱駿; 吳文權; | 書刊名 | The Kaohsiung Journal of Medical Sciences |
卷期 | 22:7 民95.07 |
頁次 | 頁321-330 |
分類號 | 416.746 |
關鍵詞 | 視網膜分枝靜脈阻塞; 玻璃體內注射triamcinolone acetonide; 黃斑部水腫; Branch retinal vein occlusion; Intravitreal triamcinolone acetonide; Macular edema; |
語文 | 英文(English) |
中文摘要 | 為了評估利用玻璃體內注射 triamcinolone acetonide 來治療因視網膜分枝靜脈阻塞而導致的黃斑部水腫,我們設計一個前瞻性、比較性、非隨機性的臨床實驗。本實驗包含了 27 個有視網膜分枝靜脈阻塞合併黃斑部水腫的病人 (共 27 顆眼睛),實驗組有 16 個病人,每位病人都接受了 4 mg triamcinolone acetonide 的玻璃體內注射,對照組有 11 個病人,每位病人都拒絕接受 triamcinolone acetonide 的玻璃體內注射。實驗組的病人其平均追蹤天數為 103.00 ± 36.24 天,對照組的病人其平均追蹤天數為 94.55 ± 36.31 天。實驗組的病人其平均視力從術前的 0.77 ± 0.43 logMAR 進步到術後的 0.44 ± 0.43 logMAR,其視力有明顯的改善 (p < 0.001),14 顆眼睛 (87.5%) 其視力有進步,其中有 10 顆眼睛 (62.5%) 其視力以 Snellen 視力表測量甚至進步至少 2 行以上。實驗組中的 16 個病人其黃斑部水腫及螢光眼底攝影的螢光劑滲漏情形在術後都有明顯改善。對照組的病人其基本最佳矯正視力與追蹤期間的最佳矯正視力相比並沒有明顯的差異 (p = 0.294)。利用玻璃體內注射 triamcinolone acetonide 來治療視網膜分枝靜脈阻塞的病人,可以改善病人的視力,使黃斑部水腫消退。 |
英文摘要 | We designed a case series study to evaluate the outcome of intravitreal triamcinolone acetonide for the treatment of macular edema due to branch retinal vein occlusion (BRVO). The prospective comparative nonrandomized clinical interventional study included 27 patients (27 eyes) with macular edema due to BRVO. The study group consisted of 16 patients who had accepted an intravitreal injection (IVI) of 4 mg triamcinolone acetonide. The control group included 11 patients without IVI of triamcinolone acetonide. The mean follow-up was 103.00 ± 36.24 days in the study group and 94.55 ± 36.31 days in the control group. In the study group, visual acuity measurements improved significantly (p < 0.001) from 0.77 ± 0.43 logarithm of minimal angle of resolution (logMAR) preoperatively to a best postoperative visual acuity of 0.44 ± 0.43 logMAR. Fourteen eyes (87.5%) gained improvement in visual acuity, with 10 eyes (62.5%) showing an increase in visual acuity of at least two Snellen lines. All 16 patients showed significant macular edema resolution in optical coherence tomography examination (p < 0.001) and perivascular leakage decrease in fluorescein angiography post-IVI. In the control group, baseline best-corrected visual acuity and best-corrected visual acuity during the follow-up did not vary significantly (p = 0.294). In conclusion, IVI of triamcinolone acetonide can lead to an increase in visual acuity and a resolution of macular edema in patients with BRVO. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。